Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pro-DenRx is a specialized pharmaceutical and dental health company that provides professional-grade preventive and therapeutic oral care products. The company's portfolio is centered on high-concentration fluoride treatments, including gels, rinses, and varnishes, as well as antimicrobial solutions such as chlorhexidine gluconate. These products are primarily utilized by dental professionals for the prevention of dental caries and the management of periodontal diseases like gingivitis. Originally established as an independent entity in 1986, Pro-DenRx underwent several ownership changes, being acquired by Zila and later Tolmar before becoming a key brand under Young Innovations in 2014. The brand is well-regarded for its innovative unit-dose delivery systems, which enhance clinical efficiency and patient safety. Today, Pro-DenRx continues to serve the dental market as a core component of Young Innovations' preventive care division.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pro-DenRx.